Aranesp, Epogen Share In CKD, ESRD Will Remain Stable Despite Hemoglobin Targets – JP Morgan
This article was originally published in The Pink Sheet Daily
Executive Summary
After surveying nephrologists, JP Morgan analysts predict that use of the erythropoiesis-stimulating agents in kidney disease settings will not change dramatically.